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Abstract
Ovarian, head and neck, and other cancers are commonly treated with cisplatin and other DNA
damaging cytotoxic agents. Altered DNA damage response (DDR) contributes to resistance of
these tumors to chemotherapies, some targeted therapies, and radiation. DDR involves multiple
protein complexes and signaling pathways, some of which are evolutionarily ancient and involve
protein orthologs conserved from yeast to humans. To identify new regulators of cisplatin-
resistance in human tumors, we integrated high throughput and curated datasets describing
yeast genes that regulate sensitivity to cisplatin and/or ionizing radiation. Next, we clustered
highly validated genes based on chemogenomic profiling, and then mapped orthologs of these
genes in expanded genomic networks for multiple metazoans, including humans. This approach
identified  an  enriched  candidate  set  of  genes  involved  in  the  regulation  of  resistance  to
radiation and/or cisplatin in humans. Direct functional assessment of selected candidate genes
using RNA interference confirmed their activity in influencing cisplatin resistance, degree of
γH2AX focus formation and ATR phosphorylation, in ovarian and head and neck cancer cell lines,
suggesting impaired DDR signaling as the driving mechanism. This work enlarges the set of
genes that may contribute to chemotherapy resistance and provides a new contextual resource
for interpreting next generation sequencing (NGS) genomic profiling of tumors.
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